Get the Stockscreener App
0.3113
4.15%
0.0124
After Hours:
.30
-0.0113
-3.63%
VolitionRX Ltd stock is traded at $0.3113, with a volume of 2.04M.
It is up +4.15% in the last 24 hours and down -29.89% over the past month.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
See More
Previous Close:
$0.2989
Open:
$0.299
24h Volume:
2.04M
Relative Volume:
1.80
Market Cap:
$38.23M
Revenue:
$1.29M
Net Income/Loss:
$-29.87M
P/E Ratio:
-0.8647
EPS:
-0.36
Net Cash Flow:
$-14.70M
1W Performance:
-5.00%
1M Performance:
-29.89%
6M Performance:
-39.61%
1Y Performance:
-54.63%
1-Day Range:
$0.2941
$0.3129
1-Week Range:
$0.2941
$0.3543
52-Week Range:
$0.2941
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
Name
VolitionRX Ltd
Sector
Industry
Phone
646 650 1351
Address
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.3113 | 36.71M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
593.25 | 224.59B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
228.46 | 163.00B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
755.96 | 61.22B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
154.37 | 44.50B | 6.95B | 1.30B | 1.09B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
231.80 | 39.50B | 15.90B | 1.28B | 2.21B | 7.2842 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | H.C. Wainwright | Buy |
| Feb-01-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-17-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-10-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-18 | Initiated | Maxim Group | Buy |
| May-14-18 | Reiterated | The Benchmark Company | Buy |
| Sep-07-16 | Reiterated | Rodman & Renshaw | Buy |
| Feb-01-16 | Initiated | Rodman & Renshaw | Buy |
View All
VolitionRX Ltd Stock (VNRX) Latest News
VolitionRX (VNRX) Analyst Rating Update: Maintain 'Buy' with $5 Target | VNRX Stock News - GuruFocus
VolitionRX Ltd (VNRX) is looking forward to a strong quarter - Setenews
VolitionRx (VNRX) Stock Surges with First Sale of Nu.Q Cancer Assays to European Cancer Center - parameter.io
VolitionRx announces first sale of Nu.Q Cancer assays to French hospital By Investing.com - Investing.com South Africa
Nu.Q Cancer Assays Sold for Certification at Lyon Center, VolitionRx (NYSE: VNRX) - Stock Titan
Freedom Capital Markets lowers VolitionRX stock price target on delayed revenue growth - Investing.com Australia
Freedom Capital Markets lowers VolitionRX stock price target on delayed revenue growth By Investing.com - Investing.com South Africa
Can VolitionRX Limited stock sustain breakout momentumEarnings Risk Report & Stepwise Trade Execution Plans - newser.com
Will VolitionRX Limited stock beat international competitionQuarterly Earnings Summary & Capital Efficient Trading Techniques - newser.com
What makes VolitionRx Limited stock attractive to growth fundsJuly 2025 Retail & Accurate Trade Setup Notifications - newser.com
Smart tools for monitoring VolitionRx Limited’s price actionWeekly Market Summary & Reliable Breakout Stock Forecasts - newser.com
How strong is VolitionRx Limited stock balance sheet2025 Major Catalysts & Safe Capital Growth Plans - newser.com
How VolitionRX Limited stock trades after rate cutsQuarterly Performance Summary & Expert-Curated Trade Recommendations - newser.com
H.C. Wainwright lowers VolitionRX stock price target on valuation update By Investing.com - Investing.com Nigeria
Are Smart Investors Making the Right Decision? VolitionRX Ltd (VNRX) - Setenews
H.C. Wainwright lowers VolitionRX stock price target on valuation update - Investing.com
VolitionRx price target lowered to $1.50 from $2.50 at H.C. Wainwright - MSN
Reynolds, Volitionrx CEO, buys $7,000 in VNRX stock By Investing.com - Investing.com Nigeria
Reynolds, Volitionrx CEO, buys $7,000 in VNRX stock - Investing.com
CEO Reynolds Buys 20,000 ($7K) Of VolitionRX Ltd [VNRX] - TradingView
[Form 4] VOLITIONRX LTD Insider Trading Activity - Stock Titan
VolitionRX (VNRX) Target Price Lowered by HC Wainwright & Co. | - GuruFocus
VolitionRX (VNRX): Analyst Jason Kolbert Reaffirms Buy Rating wi - GuruFocus
VolitionRx Limited Reports Q3 2025 Financial Growth - MSN
VolitionRx Ltd. Earnings Call Highlights Growth and Partnerships - The Globe and Mail
Using Ichimoku Cloud for VolitionRx Limited technicalsLong Setup & Detailed Earnings Play Alerts - newser.com
Is VolitionRX Limited stock resilient in recession scenariosSell Signal & High Return Trade Opportunity Guides - newser.com
VolitionRx Limited (AMEX:VNRX) Q3 2025 Earnings Call Transcript - Insider Monkey
Volitionrx Ltd earnings missed by $0.01, revenue fell short of estimates - Investing.com Nigeria
Market reaction to VolitionRx Limited’s recent newsTrade Signal Summary & Technical Pattern Based Signals - newser.com
Earnings call transcript: VolitionRx Ltd reports Q3 2025 revenue growth, stock stable - Investing.com Nigeria
Earnings call transcript: VolitionRx Ltd reports Q3 2025 revenue growth, stock stable By Investing.com - Investing.com South Africa
[SCHEDULE 13G/A] VOLITIONRX LTD SEC Filing - Stock Titan
VolitionRX Ltd (VNRX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Revenue ... By GuruFocus - Investing.com Canada
VolitionRX Ltd (VNRX) Q3 2025 Earnings Call Highlights: Strategi - GuruFocus
VolitionRX Ltd (VNRX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Revenue ... - Yahoo Finance
VolitionRX Q3 2025 Earnings Call Transcript - MarketBeat
VolitionRX: Q3 Earnings Snapshot - CTPost
Volitionrx Ltd earnings missed by $0.01, revenue fell short of estimates By Investing.com - Investing.com Canada
VNRX Advances with Strategic Partnerships and Licensing Deals - GuruFocus
[8-K] VOLITIONRX LTD Reports Material Event | VNRX SEC FilingForm 8-K - Stock Titan
VolitionRx (NYSE American: VNRX) posts Q3 revenue $0.6M; cash used in ops $3.6M - Stock Titan
Regression analysis insights on VolitionRx Limited performanceMarket Growth Review & Risk Controlled Swing Alerts - newser.com
VolitionRX Ltd (VNRX) Q3 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
VolitionRX Ltd Stock (VNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):